#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cerebral arteriovenous malformation haemorrhagic Rheumatoid arthritis Anal cancer Alpha-1 antitrypsin deficiency HER2 mutant non-small cell lung cancer Allogenic stem cell transplantation Epstein-Barr virus associated lymphoproliferative disorder Synovial sarcoma recurrent Krabbe's disease Germ cell cancer Arginase deficiency Mixed-type liposarcoma Stiff person syndrome Chronic lymphocytic leukaemia recurrent Canavan disease More trials…

    Learn about Rare Diseases

    Glomerulonephritis membranous – Diagnostics Haemophagocytic lymphohistiocytosis – Life with Disease KBG syndrome Myelodysplastic syndrome – Diagnostics Haemophilia A without inhibitors – Basic Information Retinitis pigmentosa – Trials in Disease Osteosarcoma recurrent Behcet’s syndrome – Treatment Factor IX deficiency Arterial tortuosity syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Roginolisib POTASSIUM CLAVULANATE Purified Egg Phospholipids Mps-216 Immunglobulin Prasterone Eptacog Beta (Activated) BLEXIMENIB Avb-101 Mps-106 Citric Acid H2-Receptor Antagonists KETOROLAC TROMETAMOL Candesartan Leniolisib Phosphate SIGVOTATUG VEDOTIN Acoramidis Ecoo16 Gebasaxturev Ofloxacin Hydrochloride More therapies…

    Learn about Your Condition

    Oedema Malignant melanoma stage IV Congenital pseudarthrosis Mucopolysaccharidosis Endotracheal intubation Diabetic foot infection Hairy cell leukaemia Anaemia of pregnancy Notalgia paraesthetica Glomerulonephritis Behavioural addiction Dermatitis atopic Astrocytoma malignant Arthroscopy Knee arthroplasty More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliero Universitaria Consorziale Policlinico…

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

Piazzale Giulio Cesare 11, Bari, 70124, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • Study of Tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Tozorakimab
    • Salbutamol Sulfate
    France Germany Greece Italy Poland Romania

  • Study on the 9vHPV Vaccine for Preventing Oral HPV Infections in Men Aged 20-45

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Papilloma viral infection
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    Belgium Czechia France Germany Italy Spain

  • Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Lenalidomide
    Italy

  • Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Quizartinib Dihydrochloride
    • Idarubicin Hydrochloride
    • Cytarabine
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study on Early Switching to Dolutegravir and Lamivudine for Adults with HIV-1 on Three-Drug Regimen with Virological Suppression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Dolutegravir
    • Lamivudine
    Italy

  • Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Dexamethasone Sodium Phosphate
    Italy

  • Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Melphalan
    • Bortezomib
    • Daratumumab
    Italy

  • Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Dexamethasone Sodium Phosphate
    • Lenalidomide
    Italy

  • Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Dapagliflozin
    • Irbesartan
    • Sparsentan
    Belgium Croatia Czechia Estonia France Germany +5
Previous Page
1 2 3 4 5 6 7
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!